The CDC noted that if the test yields a negative RNA NAT result, clinicians should then analyze patient serum using an IgM antibody test.
The ratings agency also assigned a Negative Rating Watch to the firm's notes offering, noting it will resolve this notation as more details of the offering become available.
Abbott said that a lawsuit it filed Thursday tries to obtain important information from Alere before its acquisition is completed.
The GenomeWeb Index fell nearly 9 percent in October, doubling back on September's 5 percent gain and underperforming the Dow and the Nasdaq.
Synlab, a European lab services provider, found the test performed well on samples with low bacterial load and non-respiratory samples.
Shareholder approval follows China's avowal that it will not block the deal and Abbott's CEO confirming his faith in Alere's business.
CEO Miles White said that he still believes that Alere is a good strategic fit for Abbott, and the firm is pursuing all of the necessary regulatory approvals for the deal.
Abbott's PCR instrument will help the biopharma companies identify isocitrate dehydrogenase mutations in patients with acute myeloid leukemia.
The court order provided a schedule of actions designed to resolve antitrust issues related to the deal.
The companies appear poised to return to court to settle Alere's claim that Abbott needs to quickly fulfill its obligations under their merger deal.
The nonprofit Biden Cancer Initiative is suspending its operations, according to the Associated Press.
Researchers examine how white nationalists handle personal genetic ancestry results that conflict with their racist worldview, the New York Times reports.
NPR speaks with research participants before and after they learn their APOE E4 status, which affects their risk of developing Alzheimer's disease.
In PLOS this week: genetic characterization of Toxoplasma gondii strains, Crimean-Congo Hemorrhagic Fever Virus uncovered in Sudan, and more.